Replacing plasmid DNA with enzymatically produced DNA in your AAV production eliminates many issues around complex or unstable sequences, purity, speed to manufacture, safety and scalability.

Many biotech and pharma companies focused on advanced therapies are taking advantage of enzymatic DNA to deliver rapid AAV production using less DNA.

Download the product brief to explore the data.